Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)—Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention?
- 5 December 2005
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 97 (2) , 33-41
- https://doi.org/10.1016/j.amjcard.2005.11.014
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- CDC/AHA Workshop on Markers of Inflammation and Cardiovascular DiseaseCirculation, 2004
- Inflammatory Markers and the Risk of Coronary Heart Disease in Men and WomenNew England Journal of Medicine, 2004
- Framingham risk score and prediction of lifetime risk for coronary heart diseaseThe American Journal of Cardiology, 2004
- Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle CellsCirculation, 2003
- Local Generation of C-Reactive Protein in Diseased Coronary Artery Venous Bypass Grafts and Normal Vascular TissueCirculation, 2003
- Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectPublished by Oxford University Press (OUP) ,2003
- C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular EventsCirculation, 2003
- Markers of Inflammation and Cardiovascular DiseaseCirculation, 2003
- Inflammation and AtherosclerosisCirculation, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001